Routine

Thrombophilia testing - indications & interpretation

thrombophilia testing · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Thrombophilia screening is of limited value in most VTE and rarely changes management; it should be targeted, correctly timed, and interpreted with awareness of how acute thrombosis and anticoagulants distort results.

Red flags

  • Thrombosis at unusual sites (cerebral, splanchnic, portal)
  • Recurrent VTE despite anticoagulation
  • Arterial and venous thrombosis together
  • Recurrent pregnancy loss with thrombosis
  • Warfarin-induced skin necrosis (protein C deficiency)

Assessment

Differential diagnosis

  • Inherited: factor V Leiden, prothrombin G20210A, protein C/S/antithrombin deficiency
  • Acquired: antiphospholipid syndrome
  • Myeloproliferative neoplasm (JAK2)
  • Paroxysmal nocturnal haemoglobinuria
  • Malignancy-associated hypercoagulability

Investigations

  • Antiphospholipid antibodies: lupus anticoagulant, anticardiolipin, anti-beta2-glycoprotein-I
  • Factor V Leiden and prothrombin G20210A gene tests
  • Protein C, protein S and antithrombin activity
  • JAK2 V617F if splanchnic/unusual-site thrombosis
  • PNH flow cytometry in appropriate settings
  • FBC and film

Management

  • Decide whether testing will change management - usually it does not after a first provoked VTE
  • Do not test routinely in provoked VTE or where lifelong anticoagulation is already indicated
  • Consider antiphospholipid testing in unprovoked VTE, arterial events, recurrent pregnancy loss or unusual sites
  • Consider heritable thrombophilia testing only where a positive result would alter management (e.g. duration, family counselling)
  • Time tests correctly: not during acute thrombosis, and account for anticoagulant interference
  • Measure protein C/S and antithrombin away from acute events and off anticoagulation (or interpret cautiously)
  • Confirm antiphospholipid antibodies on two occasions at least 12 weeks apart
  • Interpret in clinical context and counsel on absolute (not just relative) risk
  • Involve haematology for complex or discrepant results
  • Use results to guide anticoagulation duration and family counselling, not to over-treat

Drugs & doses

No drug therapy for testing itself; results may influence anticoagulant choice and duration (see VTE management)

Disposition

Outpatient / haematology-guided; counsel patients and relevant family members; integrate into anticoagulation decisions.

Complications & pitfalls

  • Misleading results during acute thrombosis or anticoagulation
  • Unnecessary anxiety and over-anticoagulation
  • False reassurance from a negative screen
  • Missed antiphospholipid syndrome if not confirmed twice
  • Inappropriate testing of asymptomatic relatives

Exam pearls

  • Heritable thrombophilia rarely changes management after a first VTE
  • Antithrombin, protein C and protein S fall during acute clot and on anticoagulants - time testing carefully
  • DOACs cause false-positive lupus anticoagulant results
  • Antiphospholipid antibodies must be persistent (repeat at 12 weeks)
  • Unusual-site thrombosis warrants JAK2 and PNH consideration

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.